Department of Clinical Medicine, University of Bergen, Bergen, Norway; Neuro-SysMed, Department of Neurology, Haukeland University Hospital, Bergen, Norway.
Department of Clinical Medicine, University of Bergen, Bergen, Norway; Neuro-SysMed, Department of Neurology, Haukeland University Hospital, Bergen, Norway.
Mult Scler Relat Disord. 2023 Feb;70:104530. doi: 10.1016/j.msard.2023.104530. Epub 2023 Jan 21.
There is increasing evidence of Epstein-Barr virus (EBV) being conditional in multiple sclerosis (MS) pathogenesis and influential for disease activity. Interferon-beta (IFNβ) is a cytokine with antiviral effects used to treat MS, in which a possible antiviral effect against EBV has been questioned. In this study, we investigated the effect of IFNβ-1a treatment on serum EBV antibody levels in 84 patients with relapsing-remitting MS. In the 18 months following IFNβ-1a treatment initiation, there were no significant associations between treatment and serum levels of Epstein-Barr nuclear antigen 1 (EBNA-1) immunoglobulin (Ig) G, early antigen (EA) IgG, viral capsid antigen (VCA) IgG or VCA IgM. The findings suggest that IFNβ-1a treatment does not influence the humoral response to EBV in patients with MS.
越来越多的证据表明，Epstein-Barr 病毒（EBV）在多发性硬化症（MS）发病机制中起条件作用，并影响疾病的活动度。干扰素-β（IFNβ）是一种具有抗病毒作用的细胞因子，用于治疗多发性硬化症，其对 EBV 的抗病毒作用曾受到质疑。在这项研究中，我们调查了 IFNβ-1a 治疗对 84 例复发缓解型多发性硬化症患者血清 EBV 抗体水平的影响。在开始 IFNβ-1a 治疗后的 18 个月内，治疗与血清 EBV 核抗原 1（EBNA-1）免疫球蛋白（Ig）G、早期抗原（EA）IgG、病毒衣壳抗原（VCA）IgG 或 VCA IgM 之间没有显著关联。这些发现表明，IFNβ-1a 治疗不会影响 MS 患者对 EBV 的体液反应。
